The Role of Tregs in Glioma-Mediated Immunosuppression: Potential Target for Intervention
- 31 January 2010
- journal article
- review article
- Published by Elsevier BV in Neurosurgery Clinics of North America
- Vol. 21 (1), 125-137
- https://doi.org/10.1016/j.nec.2009.08.012
Abstract
No abstract availableKeywords
This publication has 127 references indexed in Scilit:
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefitProceedings of the National Academy of Sciences, 2008
- A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cellsCancer Immunology, Immunotherapy, 2008
- A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T CellsClinical Cancer Research, 2008
- Immunotherapy of malignant brain tumorsImmunological Reviews, 2008
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsProceedings of the National Academy of Sciences, 2008
- Interplay between pathogenic Th17 and regulatory T cellsAnnals Of The Rheumatic Diseases, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivoBlood, 2006
- Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor–β1The Journal of Experimental Medicine, 2006
- Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic ImplicationsJournal of Clinical Oncology, 2004